BUZZ-Zoetis falls on lower sales of its pain medicine for dogs

Reuters11-05

** Shares of Zoetis fall 2.7% to $177.04

** "Investor focus has been on Librela's results in the quarter with the product missing Street expectations by ~$10mm and showing little/no sequential growth" - Brokerage J.P.Morgan

** Librela is co's osteoarthritis or arthritis pain medicine for dogs

** Co reports Q3 Librela revenue of $117 mln which is

"roughly flat versus what the company reported in Q2 and ~$10mm below what we/Street were expecting"- Brokerage J.P.Morgan

** Co now expects 2024 adj EPS between $5.86 and $5.92 vs previous forecast of $5.78 to $5.88

** ZTS also raises annual rev forecast to $9.2 bln to $9.3 bln, up from $9.1 bln to $9.25 bln previously

** Co posts Q3 adj EPS of $1.58 above Wall Street estimates of $1.46 - LSEG

** Including session moves, stock down 10.9% YTD

(Reporting by Puyaan Singh and Sneha S K)

((Puyaan.Singh@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment